Evolent Health Inc (EVH) concluded trading on Wednesday at a closing price of $11.73, with 4.33 million shares of worth about $50.81 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 5.39% during that period and on July 02, 2025 the price saw a gain of about 0.86%. Currently the company’s common shares owned by public are about 115.86M shares, out of which, 114.29M shares are available for trading.
Stock saw a price change of 9.52% in past 5 days and over the past one month there was a price change of 54.95%. Year-to-date (YTD), EVH shares are showing a performance of -38.65% which increased to 4.27% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $7.06 but also hit the highest price of $33.63 during that period. The average intraday trading volume for Evolent Health Inc shares is 2.59 million. The stock is currently trading 23.23% above its 20-day simple moving average (SMA20), while that difference is up 27.96% for SMA50 and it goes to -12.50% lower than SMA200.
Evolent Health Inc (NYSE: EVH) currently have 115.86M outstanding shares and institutions hold larger chunk of about 108.95% of that.
The stock has a current market capitalization of $1.38B and its 3Y-monthly beta is at 0.82. It has posted earnings per share of -$1.22 in the same period. It has Quick Ratio of 0.98 while making debt-to-equity ratio of 1.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EVH, volatility over the week remained 4.97% while standing at 5.85% over the month.
Stock’s fiscal year EPS is expected to drop by -13.89% while it is estimated to increase by 67.45% in next year. EPS is likely to shrink at an annualized rate of 25.00% for next 5-years, compared to annual growth of 25.98% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Needham on January 10, 2025 offering a Buy rating for the stock and assigned a target price of $15 to it. Coverage by BTIG Research stated Evolent Health Inc (EVH) stock as a Buy in their note to investors on December 03, 2024, suggesting a price target of $29 for the stock. On November 08, 2024, Stephens Downgrade their recommendations, while on October 11, 2024, KeyBanc Capital Markets Initiated their ratings for the stock with a price target of $35. Stock get a Buy rating from Truist on August 09, 2024.
